Categories
Digital Health MedTech

The Top 10 Most Valuable HealthTechCompanies in Europe (2025)

Valuation isn’t everything but in healthtech, it tells you who’s still scaling

Let’s not pretend valuation is the ultimate success metric. But it is a decent proxy for where capital, confidence and commercial traction are flowing. Especially in a market as fragmented and overregulated as European healthcare.

The 2025 leaderboard of Europe’s top 10 most valuable healthtech companies.


Not biotech. Not pharma. Just tech-enabled health. Companies at the intersection of software, care and medical delivery models. Most are private. A few are flying under the radar. And yes, Finland opens the list.

1. Oura Health (Finland)

Valuation: US$11 billion (Sep 2025)
What it does: Smart wearable ring + health analytics
Why it matters:
Europe’s wearables play moving into serious health data.

2. Doctolib (France)

Valuation: US$6.4 billion (2025 ranking) 
What it does: Appointment booking and telehealth platform for European health systems.
Why it matters: A dominant platform reaching scale across French & German markets, signalling what digital
health infrastructure looks like in the EU.

3. Sword Health (Portugal)

Valuation: US$4 billion (June 2025 funding round) 
What it does: AI-enabled digital therapy / musculoskeletal care
Why it matters: Bridges digital therapeutics and service delivery with high value healthcare cost savings.

 4. Kry International AB (Sweden)

Valuation: Reported ~US$2 billion 
What it does: Telemedicine/virtual primary care (marketed as “Livi” in UK/France)
Why it matters: One of the larger pan-European virtual care plays.

5. Cera Care (UK)

Valuation: Reported >US$1 billion (source)
What it does: Tech enabled home care & community services
Why it matters: A service delivery business scaling across UK homecare, a difficult but high impact node of the health system.

6. Flo Health (UK)

Valuation: ~US$1 billion
What it does: Women’s health (cycle tracking, fertility, health analytics)
Why it matters: Rare consumer digital health “scale” platform in Europe with global ambitions.

7. Neko Health (Sweden)

Valuation: ~US$1.8 billion
What it does: Full body scanning diagnostics with AI
Why it matters: Diagnostics and proactive screening is one of the less hyped but high upside segments in EU healthtech.

 8. Cequr SA (Switzerland)

Valuation: ~US$600 million (estimate)
What it does: Wearable insulin delivery device + patient engagement
Why it matters: Device + digital combo in chronic disease management

9. Hilo Health (Switzerland/Spain)

Valuation: ~US$300 million (estimate)
What it does: Continuous blood pressure monitoring without cuffs
Why it matters: Remote monitoring is crowded, but clinically meaningful, reimbursable models still rare.

10. Nobi BV (Belgium)

Valuation: ~US$150 million (estimate)
What it does: Smart ambient care sensors for elderly living at home
Why it matters:
A realworld aging play; modest valuation, but high relevance for Europe’s demographic shift.

What this list tells us?

Valuation follows integration. The highest valued companies are those who figured out how to embed into care delivery systems, not just launch a product or service.
It’s not just software. Many of the names here incorporate hardware or device components, but the business model leads with experience, outcomes, and scale.
Europe has range. From Portugal to Sweden to France, the value creation is not limited to London/Berlin (though they still matter).
But caution remains. Private valuations are fluid. Some said “decacorn” for Oura a year ago; latest official validated valuation is half of it at around ~$5.2bn the jump to ~$11bn comes from news speculation.

One Last Note

This list isn’t final, and it will change, maybe an hour after the publication. Private valuations shift. Some firms may consolidate or pivot. But if you’re looking to invest, compete or expand — these are the healthtech
companies dominating European healthtech headlines for now.

Next up: where the money’s coming from — and who’s still writing the big cheques.

This content has been enhanced with GenAI.

Categories
Digital Health MedTech

Mapping the European HealthTech Goldmine

What’s scaling, who’s paying, and why you should care

Let’s start with a question.
What do Oura, Sword Health, and Doctolib have in common?

If you said “healthtech unicorns” you’re technically right, but that’s not the real answer.
The real answer: they’re European, they’re growing like weeds, and most investors or founders still talk about them like they’re niche side projects.

Which is odd. Because these are the companies quietly shaping the future of healthcare on the old continent, while half the market’s still arguing about whether DiGA is dead or just very German.

So, I’ve put together something to help.

This is Mapping the European HealthTech Goldmine.
A five-part series for anyone building, backing, or expanding healthtech in Europe.

Why now?

Because the money’s back.

After the hangover that was 2023, last year saw European healthtech bounce to around $4.8 billion in VC funding. This year? $4.3 billion in Q1 alone, and that’s not even counting what gets tucked into medtech, diagnostics, or things with “AI” bolted on just to close a round.

The capital is flowing. But, and this is where it gets interesting, it’s not flowing evenly.

It’s going to:

  • A handful of markets (Finland? Really? Yes.)
  • A small set of models (wearables, MSK, diagnostics-as-a-service)
  • And companies that figured out how to integrate with public health systems without losing their will to live.

What you’ll actually get

No vague “trends”. No breathless “disruption” language, this you have in the name of this website. I offer just five posts that get to the point:

  1. The Top 10 Most Valuable HealthTech Companies in Europe
    Valuation league table, explained, and why some are quietly stalling.
  2. Who’s Funding the Boom?
    The VCs, public funds, and CVCs writing cheques in 2025.
  3. 2024 vs 2025: Where the Money’s Really Coming From
    VC vs grants vs corporate with actual (well, approximated) numbers.
  4. Best Places to Launch or Scale a HealthTech Company in Europe
    Spoiler: it’s not always Berlin or London.
  5. What Europe’s HealthTech Winners Did Differently
    (Besides surviving long enough to be acquired.)

Who this is for

If you’re a founder, an investor, or someone trying to scale something in European healthcare without losing your shirt — this is for you.

Especially if you’re tired of reading loud headlines about $20M Series A rounds in the US and wondering why your reimbursement pilot takes 18 months and a PowerPoint deck for the bored Ministry officials.

Read it, steal ideas from it, or forward it to your CFO

The first post, the top 10 most valuable healthtech companies in Europe goes live next.

After that, one post a week, give or take.
Short reads. Linked data. Unapologetically European perspective.

If that sounds useful, subscribe, bookmark, or just come back with coffee.

See you in the series.

Exit mobile version